Mayne Pharma Group (ASX:MYX) said that during the period from July to November, its net revenues were AU$165 million, falling 5.5% from the same period in the previous year, according to a Monday Australian bourse filing.

The Women's Health sector was flat at $50.8 million while dermatology was down 12% to $37.1 million over the same period. The Women's Health sector saw continued growth with demand for total prescriptions showing continued volume growth through the first five months of fiscal year 2026.

Underlying earnings before interest, taxes, depreciation, and amortization for the period was AU$11.5 million compared to the prior-year EBITDA of AU$22.4 million.